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MutagenesisThe FG extended loop in domain III of the dengue virus type 2 (DENV2) envelope protein is postulated to be a
molecular determinant for host cell infectivity. To determine the contribution of the FG loop to virus
infectivity, an infectious cDNA clone of DENV2 was manipulated by deleting amino acids in the loop (VEPGΔ)
to mimic tick-borne ﬂaviviruses or by substituting these AAs with RGD or RGDK/S to mimic motifs present in
other mosquito-borne ﬂaviviruses. We found the FG loop to be dispensable for infection of C6/36 cells but
critical for infection of Aedes aegypti mosquito midguts and mammalian cells. All the FG loop mutants were
able to bind to and enter mammalian cells but replication of VEPGΔ in Vero cells at 37 °C was delayed until
acquisition of secondary mutations. Reduced binding of DENV2 type-speciﬁc monoclonal antibody 3H5 to
mutant viruses conﬁrmed the FG loop motif as its target epitope., Immunology, and Pathology,
92 Campus Delivery, Colorado
Y, USA.
USA.
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Dengue viruses (DENVs) are themostmedically important arthropod-
borne viruses infecting humans today. The DENVs comprise a serocom-
plex in the family Flaviviridae, genus Flavivirus that includes DENV
serotypes 1–4 (DENV1–4) and are the etiological agents of dengue fever
and dengue hemorrhagic fever/dengue shock syndrome. Approximately
one thirdof theworld's population is at riskof becoming infectedbyDENV
due to the distribution of their primary vector, Aedes aegypti (Gubler,
1998). While there are licensed vaccines for other medically important
ﬂaviviruses such as Japanese encephalitis virus (JEV), yellow fever virus
(YFV), and tick-borne encephalitis virus (TBEV), no currently licensed
vaccines or antiviral drugs are available for dengue.
Flaviviruses are composed of a capsid protein core complexedwith a
positive sense RNA genome (~11 kb), surrounded by a lipid envelope.
The envelope contains 180 copies of the envelope (E) protein,which are
arranged in an icosahedral scaffold of 90 homodimers that lie parallel to
the virion surface (Kuhn et al., 2002). The DENV E protein is a class IIfusion protein responsible for host cell attachment, entry, and virus-
mediated cell membrane fusion. The 2 Å crystal structure has been
solved for the ectodomain of the TBEV (Rey et al., 1995), DENV2 (Modis
et al., 2003), DENV3 (Modis et al., 2005), and West Nile virus (Kanai
et al., 2006) E proteins revealing three important structural domains
(DI, DII, and DIII), which correlate with earlier monoclonal antibody
(MAb)mapping data that deﬁned three antigenic domains (C, A, and B)
(Heinz, 1986; Mandl et al., 1989; Roehrig et al., 1998, 1990). Domains
I and II are linearly discontinuous structures separated by four peptide
strands that comprise a molecular hinge region. The ﬂavivirus-
conserved fusion peptide (cd loop, amino acids [AAs] 98–111), located
at the distal end of DII is responsible for E protein insertion into the
endosomal membrane and subsequent fusion of the host membrane
and viral envelope (Modis et al., 2004). DIII is an immunoglobulin-like
structure connected to DI by a single linker peptide and is postulated to
have host-cell receptor binding properties. Antibodies with high
neutralizing activity have been mapped to DIII epitopes and soluble
DIII has been used to block infection of cells with whole virus, both
suggesting that DIII contains receptor–ligand epitopes (Abd-Jamil et al.,
2008; Chin et al., 2007; Chu et al., 2005; Crill and Roehrig, 2001; Huerta
et al., 2008; Roehrig et al., 1998).
The DENV2 and TBEV E protein structures only differ noticeably at
surface exposed loops. One major difference in surface structure is
located in DIII, where DENV2 has an extended loop motif between the
F and G beta strands (FG loop) while TBEV does not (Fig. 1) (Rey et al.,
1995; Zhang et al., 2004). The extended portion of this loop is composed
Fig. 1. E protein structure and location of AA on the lateral ridge of DIII. (A) Top-downviewof the DENV2 E proteinmonomerwith DI in red, DII in yellow, andDIII in blue. (B) Side-view of
theDENV2 E proteinmonomer. (C) Side-view of DENV2 E protein DIII and Omsk hemorrhagic fever virus (OHFV or TBEV) E protein DIII. The A beta strand (cyan), the FG loop (green), and
K122 (magenta) are highlighted. Protein structureswere obtained from the proteindatabase bank (DENV2 E protein homodimer ID: 1oan, DENV2DIII ID: 2jsf, andOHFVDIII ID: 1z3r) and
were rendered using Polyview-3D (Porollo et al., 2004).
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in tick-borne ﬂaviviruses (Table 1, Fig. 1). The absence of the extended
loop in the tick-borne viruses has implicated the FG loop as a mosquito
cell-speciﬁc binding motif. In addition, the four central AAs comprising
this loop vary between each DENV serotype and are suggested to be
involved with binding to mosquito cells in a serotype-speciﬁc manner,
while binding of DIII to mammalian cell lines is suspected to be
independent of the FG loop (Hung et al., 2004).Table 1
Domain III FG extended loop amino acid sequences for vector-borne ﬂaviviruses.
Virus Strain FG loop sequence (AAs 381–386)a Accession number
DENV-2 16681 G VEPG Q AAB58782
DENV-1 16007 G AGEK A AAF59976
DENV-3 PhMH-J1-97 G IGDK A AAS49486
DENV-4 Thailand/1985 G VGDS A AAV49746
YFV Asibi G TGDS R AAT58050
YFV 17D G RGDS R AAX47570
JEV Nakayama G RGDK Q AAB40688
MVE NG156 G RGDK Q ABM65594
WNV NY99 G RGEQ Q AAF20092
SLEV Laderle G RGTT Q ACA28960
TBEV Neudoerﬂ G ———— E AAA86870
OHFV S-4-7/9867 G ———— E AAO65829
a E protein AA position in DENV-2 16681.In this study we investigated the importance of the DENV2 FG loop
for infection of mammalian and mosquito cell cultures and live
mosquitoes. Site-directed mutagenesis was used to delete or substitute
AAs in the FG loop of DIII in an infectious cDNA clone of DENV2 strain
16681 to mimic the tick-borne viruses, JEV, and YFV17D. The results of
this study show that the FG loop is critical for virus infectivity of cultured
mammalian cells and A. aegyptimidguts.
Results
Rationale for mutagenesis of the FG extended loop
Epitopes recognized by DENV type-speciﬁc antibodies have been
mapped to a surface exposed amino acidmotif in the E protein located on
the lateral ridge of DIII that forms the FG extended loop (Gentry et al.,
1982; Gromowski et al., 2008; Hiramatsu et al., 1996; Sukupolvi-Petty
et al., 2007). To investigate the involvement of the DENV2 FG loop
(speciﬁcally AAs 382–385; VEPG) in viral replication, we used site-
directed mutagenesis of the E protein gene of DENV2 strain 16681
infectious cDNA clone 30P-NBX (Huang et al., 2010) to alter the VEPG
sequence. The ﬂaviviruses in the JEV serocomplex and YFV have a semi-
conserved RGD integrin-bindingmotif as part of the FG loop, and changes
to this motif have been shown to affect the ability of viruses to infect
vertebrate and invertebrate cells (Hahn et al., 1987; Lee and Lobigs, 2000;
Lobigs et al., 1990; van der Most et al., 1999). The mutations we
330 S.M. Erb et al. / Virology 406 (2010) 328–335introduced into the E gene of the full length DENV2 infectious clonewere
VEPGΔ (deletion), VEP382RGD (RGD), VEPG382RGDK (RGDK), and
VEPG382RGDS (RGDS) (substitutions). Changing VEP to RGD inserts a
known integrin-bindingmotif and changes the DENV2 type-speciﬁcity of
the FG loop. More speciﬁcally, mutating VEPG to RGDK or RGDS imitates
theFG loops found in JEVandYFV17D, respectively (Table1).Additionally,
we completely deleted the FG loop, mimicking the tick-borne ﬂaviviral
E protein.
Transfection and recovery of infectious virus from C6/36 cells
After site-directed mutagenesis to introduce nucleotide substitutions
into the E gene of the DENV2 infectious cDNA clone, infectious RNA was
transcribed in vitro and transfected into C6/36 cells (C-0). All mutant
viruseswere able to replicate inC6/36cells after transfection as evidenced
by detectable virus antigen in cells and virus genome in medium. After
passage of resulting C-0 virus to naive C6/36 cells (C-1), virus antigen and
virus genome were again detected, conﬁrming the ability of all mutant
viruses to infect this cell type. Sequencing the genomes of C-1 viruses
showed that each mutant had the expected full length genome sequence
(Table 2), and therefore C-1 seeds were used for all subsequent
phenotypic studies. The recovery of all four mutant viruses from C-0
andC-1 samples demonstrated thatDENV2 infectivity of C6/36 cells is not
dependent on the presence or sequence of the FG loop.
Transfection and recovery of virus from Vero cells
To investigate the ability of these mutant viruses to infect and
replicate in mammalian cells, mutant virus RNA was transfected into
(V-0) and resulting virus was passaged once in Vero cells (V-1).
Full-genome sequencing of V-1 samples revealed mixed populations in
which virus genomes retained the desired mutations and partially
gained a mutation in the envelope gene, K122I/K (mixed consensus
sequence veriﬁed by cDNA sequencing in both directions). V-0 genome
sequencing showed that mutants VEPGΔ and RGDK acquired this
additional mutation following transfection while mutants RGD and
RGDSdidnot have this changeuntil the subsequentpassage. In addition,
themixedpopulation V-0 genomes formutantVEPGΔhad an additional
K388E/K mutation in the envelope protein, which was retained in the
V-1 seed. Due to the instability of these mutants in Vero cells, all the
mutant seeds used for further phenotype studies were derived from
C6/36 cells (C-1).
Epitope mapping of mutant viruses
A well-deﬁned panel of murine MAbs that recognize all three
distinct antigenic domains of the E protein was used to investigateTable 2
Transfection and recovery of infectious virus in C6/36 or Vero cells.
Virus C6/36 cells Vero cells
C-0/C-1a
virus
recovery
C-0/C-1b
E protein
sequence
V-0/V-1a
virus
recovery
V-0b
E protein
sequence
V-1b
E protein
sequence
VEPGΔ +/+ Correct +/+ +K122I/K
+K388K/E
+K122I/K
+K388E/K
RGD +/+ Correct +/+ Correct +K122K/I
RGDK +/+ Correct +/+ +K122K/I +K122I/K
RGDS +/+ Correct +/+ Correct +K122I/K
a Transfection (C-0 or V-0) and passage (C-1 or V-1) were considered positive if virus
antigen and virus genome were detected by IFA and RT-PCR, respectively.
b Sequencing veriﬁed that all mutants contained the desired mutations. Mutants
with no additional changes in the genome (correct), and secondary mutations in the E
protein are speciﬁed.whether epitopes in the E protein are affected by mutation of the FG
loop (Roehrig et al., 1998). Antibody reactivity was assessed by
immunoﬂuorescent assays (IFA) on acetone-ﬁxed C6/36 cells infected
with each virus. MAb 3H5was the only antibody to show a decrease in
binding greater than 4-fold for all mutants compared to wild type
(wt) 30P-NBX (data not shown). This corroborates results from other
researchers who have shown that the FG loop is the binding site for
this type-speciﬁc antibody (Gromowski et al., 2008; Hiramatsu et al.,
1996; Sukupolvi-Petty et al., 2007; Trirawatanapong et al., 1992).Virus growth kinetics in C6/36, Vero, and HepG2 cells
Mutant virus growth kinetics were determined by infecting cell
cultures in duplicate with each virus at a multiplicity of infection (MOI)
of 0.001 and measuring virus genomic equivalents in medium by
quantitative (q)RT-PCR every two days. Given the genetic stability of
these mutant viruses in C6/36 cells and their genetic instability in Vero
cells, infectious virus titers of selected sampleswere determined using a
C6/36 cell-based 50% tissue culture infectious dose (TCID50) assay.
Genome equivalents achieved by day 8 and peak infectious titers are
reported in Table 3.
All four mutant viruses had similar replication kinetics and peak
infectious titers in invertebrate C6/36 cells compared to wt virus,
corroborating the C6/36 cell transfection data and the ability of the FG
loop mutant viruses to infect and replicate efﬁciently in these cells. In
contrast, mutant virus growth kinetics in mammalian cells was more
variable. By day 10 pi in Vero cells, mutants RGD, RGDK, and RGDS
reached similar genome equivalent (ge) levels to wt virus, although
replication before this day was delayed compared to wt (Fig. 2A).
Sequencing genomes of virus harvested at the completion of each
growth curve showed that mutants RGD and RGDS were genetically
stable, while RGDK generated a mixed population with an additional
K122K/I mutation. Mutant VEPGΔ replication kinetics differed greatly
fromtheothermutants inVero cells. Duplicate growthcurves forVEPGΔ
yielded two different results. Both infections showed no genome
replication until day 6 pi, then only one of two cultures demonstrated
increased replication kinetics (Fig. 2A) and attained a low peak
infectious virus titer of 3.38 log10 TCID50/ml (Table 3). Virus genome
sequences from the culture exhibiting genome replication contained an
additional K122I mutation, similar to mutant RGDK and the V-0 virus
resulting from transfection. The temperature sensitivity of mutant
VEPGΔ in Vero cells was investigated by comparison of growth at 28 °C
and 37 °C. Replication of mutant VEPGΔ from days 2 to 6 pi was slower
at 37 °C than at 28 °C, but the replication rate was more rapid at 37 °C
than at 28 °C after day 8 pi (Fig. 2B). Viral genome sequencing revealed
no additional genome sequence changes in mutant VEPGΔ at 28 °C,
while additional E proteinmutations occurred in both samples cultured
at 37 °C. One culture acquired K122K/I and N390H mutations, and the
other had additional K122K/I, N390N/H, and Q400H/Q mutations.
These data suggest that the VEPGΔ deletion may have rendered the
virus thermally unstable at 37 °C until extra mutations were evolved.
Mutant virus phenotypes also were analyzed in HepG2 cells.
Replication kinetics and peak infectious titer of mutant RGD were
similar to 30P-NBX after infection of HepG2 cells, in stark contrast to
mutant VEPGΔ, whichwas unable to produce infectious virus in this cell
type. Although there was no detectable infectious virus, low level
increases (12-fold above input) of viral genome equivalents were
detected by qRT-PCR between day 0 and day 8 pi, suggesting that virus
could enter these cells but could not complete a productive infectious
cycle. This contrasts to the other mutants, which had 102–104-fold viral
RNA increases, while wt viral RNA increased more than 105-fold
between day 0 and day 8. Genome replication of mutants RGDK and
RGDS was reduced by 32- and 10-fold compared to wt, respectively.
Also, their peak infectious titerswere lower thanwt by 50- to 1000-fold
(Table 3).
Table 3
Genome equivalents and peak infectious virus titers in invertebrate and vertebrate cell lines.
Virus C6/36 Vero HepG2
ge/mla TCID50/mlb ge/ml TCID50/ml ge/ml TCID50/ml
30P-NBX 10.81±0.08 8.75±0.00 10.16±0.05 6.88±0.18 9.06±0.08 6.25±0.35
VEPGΔ 10.85±0.11 8.50±0.35 4.57c±0.70 3.38c±1.59 6.38±0.14 Lethal
RGD 10.93±0.01 9.00±0.35 9.21±0.02 7.25±0.71 9.14±0.05 5.75±0.35
RGDK 10.68±0.03 8.63±0.18 8.60c±0.02 5.75c±0.00 7.46±0.18 3.00±0.35
RGDS 10.56±0.09 9.13±0.53 9.19±0.00 6.63±0.18 8.01±0.09 4.50±0.35
a Geometric mean log10 ge/ml on day 8 post infection.
b Peak log10 TCID50/ml achieved during growth curves.
c Virus acquired a K122I mutation in the E protein.
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Adult female A. aegypti RexD mosquitoes were presented with an
infectious blood-meal to determine if mutations in the FG loop affected
mosquito midgut infectivity. RGD, RGDK, and RGDS mutant viruses did
not have statistically different midgut infection rates (MIRs) from wt
30P-NBX. However, mutant VEPGΔ had a signiﬁcantly lower MIR than
30P-NBX, in contrast to the ability of this virus to efﬁciently infect C6/36
cells (Fig. 3).
The lowMIR of the parent virus 30P-NBXmade it difﬁcult to analyze
differences between wt and mutant viruses in infection of other
mosquito tissues after dissemination. In order to investigate the ability
of these mutants to infect mosquito tissues outside the midgut,
dissemination was bypassed by intrathoracic (IT) inoculation of
mosquitoes with 30–50 TCID50 of virus, a concentration previously
used to show signiﬁcant differences in mutant virus infectivity ofFig. 2. Virus growth kinetics in Vero cells at 37 °C and 28 °C. Vero cells grown at 37 °C or
28 °C were infected with wt or mutant viruses at a MOI of 0.001 and replication was
measured via qRT-PCR of virus genome RNA inmedium every two days for twelve days.
(A) Growth of FG loop mutant viruses at 37 °C. The data presented are geometric mean
titers (in log10 genome equivalents/ml) from duplicate ﬂasks infected and maintained
at 37 °C except for VEPGΔ and VEPGΔ+K122I, which represent results from individual
ﬂasks. (B) Temperature sensitivity of the VEPGΔ mutant. Data are geometric mean
titers (log10 genome equivalents/ml) from duplicate ﬂasks infected and maintained at
37 °C or 28 °C.mosquito tissues (Huang et al., 2010). After IT inoculation, infectious
virus replicates in permissive tissues in contact with the mosquito
hemolymph, including nervous tissue in the head. By 7 days pi,
accumulation of viral antigen in the head indicates ampliﬁcation of
injected virus, suggesting no requirement for adaptive mutations.
Mutants VEPGΔ, RGDK, and RGDS were less efﬁcient at infecting
mosquito head tissues compared to 30P-NBX, as indicated by their
signiﬁcantly different infection rates. Mutant RGD infection rate for
tissues in the head was similar to wt (Fig. 3). These data clearly show a
disparity between DENV FG loop mutant infection of C6/36 cells and
infection of mosquito tissues.
Fusion competence of FG extended loop mutant viruses
The ability of the dengue virion to escape the host cell endosome
before degradation in lysosomes is an important step in the life cycle of
the virus and ismediated by the cd loop located at the distal end of DII of
the E protein monomer. Our fusion from within (FFWI) assay results
using infected C6/36 cells showed no signiﬁcant difference in fusion
activity at a pH range of 5.5 to 7.5 for any of the FG loopmutant viruses
compared to 30P-NBX (data not shown), conﬁrming that these FG
mutations in DIII did not affect the cd loop fusion function.
Discussion
Previous studies have implied that DIII of the ﬂaviviral E protein is
required for attachment to and infection of susceptible cells. Soluble DIII
of the DENV E protein can block binding to multiple cultured cell types
by homologous and heterologous DENV serotypes (Chin et al., 2007;
Hung et al., 2004). Hung et al. (2004) found that binding of solubleFig. 3. Virus MIR post oral infection and virus head infection rates post IT inoculation.
Aedes aegypti RexD strain mosquitoes were presented an infectious blood-meal or IT
inoculated with virus, and maintained for seven days until the midguts or heads were
dissected. IFA was used to detect virus antigen and infection rates were calculated.
Experiments were repeated at least three times. Student's t test was used to calculate
signiﬁcance (*p-valueb0.05) for MIR and chi-square analysis was used to calculate
signiﬁcance for head infection rates (**p-valueb0.05) as compared to 30P-NBX,
respectively.
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containing the homologous FG loop sequence, but not by heterologous
peptides containing FG loop sequences of other DENV serotypes.
Additionally, these peptides were unable to block either homologous
or heterologous DIII binding to BHK-21 cells. These results and the
absence of the FG loop in the tick-borne viruses (Table 1), which
typically are not able to infect C6/36 cells, led to speculation that the FG
loop plays a speciﬁc role in binding invertebrate cells but not
mammalian cells. However, the results of our study suggest that the
DIII FG loop structure is important for infection and replication in
mammalian cells as well as mosquito tissues, but a speciﬁc amino acid
sequence is not required. Our results also showed that neither the
speciﬁc VEPG sequence nor the FG loop structure was an important
determinant of cultured C6/36 mosquito cell infection by DENV2.
Other studieshave indicated that the receptors and/or entrypathways
for DENV infection of C6/36 cells might be atypical. A previous report
utilizing a chimera containing Langat virus (tick-borne ﬂavivirus) prM/E
genes on a DENV4 nonstructural gene backbone showed that this virus
was able to infect and replicate efﬁciently in C6/36 cells, while the wt
Langat virus could not, implying that the C6/36 cell infection restriction
for Langat virus is due to the nonstructural genes and not the E
glycoprotein (Pletnev and Men, 1998). Both our results and those of
Pletnev andMen (1998) suggest that other structures or sequencemotifs
in the E protein are responsible for binding to and entry of C6/36 cells.
Additionally, although there is evidence thatﬂaviviruses enter C6/36 cells
by receptormediated endocytosis (Acosta et al., 2008; Chu andNg, 2004a,
b;Mossoet al., 2008), it has alsobeensuggested thatﬂaviviruses can infect
these cells by direct fusionwith the plasmamembrane (Hase et al., 1989a,
b; Nawa et al., 2007). It is widely assumed that DENV replication in C6/36
cells is a useful model for predicting viral replication in live adult
mosquitoes; however, our studies and others have shown that this is not
necessarily the case. A previous study showed that E protein glycosylation
was critical for growth in Vero and C6/36 cells but not for growth in A.
aegypti mosquitoes (Bryant et al., 2007). Additionally, we found that
DENV2 E protein fusion peptide mutants could replicate to high titer in
C6/36 cells but had signiﬁcantly lower infection rates inmosquitoes after
IT inoculation (Huang et al., 2010).
We showed that the AA sequence of the FG loop is unimportant
compared to the presence of the structure itself for mosquito midgut
infection. The low MIR resulting from deletion of the FG loop may be
due to one of the following: (i) Absence of this loop may reduce viral
attachment/entry to midgut cells, suggesting either the FG loop is
directly involved in interaction with midgut cell receptors or deletion
of the loop results in changes in other DIII structures necessary for
efﬁcient receptor binding/cell entry. (ii) Absence of the FG loop may
affect E protein folding/maturation in midgut cells, resulting in
reduced assembly of infectious progeny virions.
IT inoculation of virus into mosquitoes has been shown to be a
sensitive method for growing DENVs that cannot be cultured readily in
other systems (Rosen and Gubler, 1974) and it was employed in this
study to analyze the infection rates of the FG loop mutant viruses in
tissues outside themidgut. In addition tomutant VEPGΔ, mutants RGDS
and RGDK had signiﬁcantly lower infection rates than 30P-NBX in
mosquito head tissues. Mutant RGDK and RGDS FG loop motifs mimic
those found in DIII of JEV and YFV17D, respectively, and both of these
viruses are capable of replicating in A. aegypti mosquitoes after IT
inoculation (Bhatt et al., 2000;McElroy et al., 2006). Since the RGD virus
had similar infection rates to wt virus in head tissues, it appears that in
the context of DENV2DIII, substitution of glycine at position 385 ismost
detrimental to virus replication in these tissues. Thedifferent FG loopAA
sequence for each of the DENV serotypes may affect the binding afﬁnity
of the loop to different cell types, but it is likely that the loop structure
itself ismost important for infectivity of various cell types. Further work
utilizing infectious clones with the 3 other serotype FG loop sequences
will be necessary to fully understand the role of the serotype-speciﬁc
sequence of the FG loop in DENV infection.A surprising ﬁnding in this studywas that the FG loop affects DENV2
infection of mammalian cells. Our results indicated that deletion of AAs
382–385 signiﬁcantly impaired virus replication in mammalian cells,
although VEPGΔwas able to enter cells to initiate virus replication. This
ﬁnding is consonant with the previous report that the FG loop is not
important for DENV2 binding to mammalian cells (Hung et al., 2004).
Growth of the deletionmutant at 37 °Cwas slower than at 28 °C for the
ﬁrst 8 days until additional mutations evolved at 37 °C, suggesting that
this mutant virus may be thermally unstable at 37 °C. Similarly,
mutations introduced into the FG loop of YFV17D were found to affect
protein stability at 37 °C, but not mammalian host cell attachment
(van der Most et al., 1999). VEPGΔ and the other FG loop mutants
acquired the K122Imutation after transfection (RGDK) or passage (RGD
and RGDS) in Vero cells, implying that this mutation is a Vero cell
adaptation. Interestingly, viruses with engineered mutations in the
molecular hinge region of the E protein also acquired this K122I
mutation following transfection of Vero cells, suggesting that this
mutationmay not speciﬁcally compensate for alterations in the FG loop
(C.Y-HHuang unpublished data). In addition, we have previously found
a K122E mutation in wt DENV2 strain 16681 after multiple Vero cell
passages (C.Y-H Huang personal communication), suggesting that the
mutation at K122 may be primarily a primate cell culture-adaptive
mutation for DENV2.
Substitution of VEP by the integrin-binding motif RGD did not
affect DENV2 infection of mosquitoes and had minimal effects on
growth in cultured cells, suggesting that the integrin binding motif
could also be utilized by DENV2 in host infection. However, additional
substitutions at AA 385 signiﬁcantly reduced infection of mosquito
head tissues, suggesting that RGDK or RGDSmotifs are not optimal for
DENV infection in A. aegypti. It is possible that the AA motif in the FG
loop is a determinant of vector selection/preference considering that
none of the DENV serotypes has the RGD motif, whereas most of the
ﬂaviviruses with the RGD motif naturally occurring in the FG loop are
transmitted by Culex spp. mosquitoes.
If the FG loop contributes to receptor binding, it may be either in
concert with or independently from another ligand on the E protein.
Several groups have identiﬁed putative cell receptors capable of binding
DENV E protein on mammalian and invertebrate host cells that include
glycosaminoglycans (Vero and BHK21) (Chen et al., 1997; Hung et al.,
2004; Hung et al., 1999), heat shock proteins (U937 and C6/36)
(Salas-Benito et al., 2007; Valle et al., 2005), stress response protein
Grp78 (HepG2) (Jindadamrongwech et al., 2004), DC-SIGN (monocyte-
derived dendritic cells) (Navarro-Sanchez et al., 2003; Tassaneetrithep
et al., 2003), mannose receptor (macrophages) (Miller et al., 2008), and
other as yet unidentiﬁed proteins of various sizes (Vero, C6/36, and
mosquito midgut cells) (Martinez-Barragan and Del Angel, 2001;
Mercado-Curiel et al., 2006) indicating that the E protein may be capable
of attaching to different cellular receptors via several E protein motifs.
In this study we showed that only binding of the type-speciﬁc,
strongly neutralizing MAb 3H5 is abolished by deletion or substitution
of AAs in the FG loop. MAb 3H5 binds to the DENV2 conserved FG loop
AAs E383 and P384 as well as semi-conserved G304 and K305 on the
neighboring A beta strand (Gromowski and Barrett, 2007; Gromowski
et al., 2008; Roehrig et al., 1998; Sukupolvi-Petty et al., 2007). Binding of
subcomplex-speciﬁc MAb 1A1D-2, which targets AAs on the A strand
(K305/307/310), was not affected by mutation of the FG loop,
demonstrating that the antigenic structure of the A strand was still
intact (Lok et al., 2008; Roehrig et al., 1998; Sukupolvi-Petty et al., 2007).
Evidence that a peptide containing the DENV2 FG loop sequence did not
reduce binding of DENV2 DIII to mammalian cells (Hung et al., 2004)
suggests that a common attachment site apart from the FG loop in DIII
has a role in binding to vertebrate cells. Additionally, as depicted in Fig. 4
by Zhang et al. (2004), the FG loop may be important for forming a
hydrogen bond network with the A strand around the 5-fold axis in the
mature virion that could help maintain the structural integrity of the
icosahedral protein scaffold, aiding in thermal stability and providing a
333S.M. Erb et al. / Virology 406 (2010) 328–335concentration ofmultiple attachment siteswithin close proximity. If the
FG loop was responsible for binding to one particular receptor, it is
possible that other structures inDIII suchas theA strand, or other sites in
DII could bind to co-receptors and partially compensate for the absence
of the FG loop in the VEPGΔ mutant. However, deletion of VEPG may
decrease the overall efﬁciency of virus entry, resulting in suboptimal
virus infection invertebrate cells. Thepresenceofother receptorbinding
sites outside DIII could have implications for vaccine design and may
explain why DIII-speciﬁc antibodies seem to play a minor role in
neutralization of DENV by human sera (Wahala et al., 2009). Binding
assays usingmutant VEPGΔmay be successful in discerningwhat other
E protein structures contribute to receptor binding and could help
determine if DENV E protein attachment to host cells is indeed a
multistep process. We are currently performing these binding experi-
ments with Vero cells.
The ﬁndings of this study emphasize the importance of the FG loop
in DENV infection of mosquitoes; however, they do not determine if
the presence of the VEPG loop alone is sufﬁcient for mosquito
infection, nor why tick-borne ﬂaviviruses lack this structure. The
results provide additional evidence that C6/36 cells are not a
complete surrogate for DENV replication in mosquitoes and also
point to the importance of using whole virus particles for analyzing
the effect of mutations on the biology of the E protein.
Methods and materials
Cell culture
Vero and HepG2 cells were grown at 37 °C in Dulbecco's modiﬁed
Eagle's mediumwith 10% fetal bovine serum (FBS). C6/36 cells used for
virusphenotyping experimentswere grown inYE-LAHmedium(Huang
et al., 2000) and C6/36 cells used for virus propagation to infect
mosquitoes were grown in Leibovitz L-15 medium, both at 28 °C with
10% FBS.
Mutagenesis, transfection, and virus recovery
DENV2 strain 16681 infectious cDNA plasmid, pD2/IC 30P-NBX
(Huang et al., 2010) was modiﬁed from pD2/IC-30P-A (Kinney et al.,
1997) and used to construct all mutant viruses. QuikChange site-
directed Mutagenesis kit (Stratagene) was utilized to engineer desired
mutations into the E gene of the cDNA plasmid. Mutations engineered
into the E gene were a VEPG382 motif deletion, VEP382RGD,
VEPG382RGDK, and VEPG382RGDS. Virus derived from the parental
plasmid (30P-NBX) has a similar phenotype to DENV2 strain 16681 and
was used as the positive control for all experiments.
Transfection of Vero and C6/36 cells with infectious vRNA has
been described previously (Huang et al., 2010, 2003). Brieﬂy, 200 ng
of linearized infectious clone cDNA was transcribed in vitro using the
Ampliscribe T7 High-yield transcription kit (EPICENTRE Biotechnol-
ogies) and the recovered RNA was electroporated into 4×106 Vero
cells or 8×106 C6/36 cells using the BioRad Gene Pulser Xcell system.
Electroporated cells were seeded into a 75 cm2 ﬂask and maintained
for 10–14 days until the virus was harvested. Medium harvested from
transfected Vero cells (V-0) or C6/36 cells (C-0) was centrifuged to
remove cell debris, supplemented with 20% FBS, and stored at−80 °C.
An aliquot of V-0 and C-0 was used to infect naive Vero and C6/36
cells to produce V-1 and C-1 seeds, respectively. Genome cDNA of V-1
and C-1 seeds were fully sequenced to evaluate their genomic stability
as described before (Huang et al., 2010). Medium from transfected
and infected cells was subjected to RT-PCR to detect the presence of
viral genomes. Viral antigenwas detected in acetone-ﬁxed cells by IFA
using polyclonal anti-DENV2 New Guinea C hyperimmune mouse
ascitic ﬂuid (HMAF) and ﬂuorescein isothiocyanate-conjugated (FITC)
goat anti-mouse IgG (Jackson Immunoresearch Laboratories).Assay of DENV2 growth kinetics in cell cultures
Twelve day growth curves were performed to investigate mutant
virus growth kinetics in different cell types. Cell cultures were infected
in duplicate at a MOI of 0.001 and virus genomic equivalents were
measured by qRT-PCR (Butrapet et al., 2006). Samples with peak
qRT-PCR titerswere assayed for infectious virus by TCID50 in C6/36 cells
(Bryant et al., 2007; Huang et al., 2010).
A. aegypti mosquito infection by blood-feeding and intrathoracic inoculation
A. aegypti RexD strain laboratory mosquitoes originating from
Rexville, Puerto Rico, were reared from eggs and maintained as adults
at 28 °C, and 80% relative humidity with a photocycle of 12 h
light:12 h dark. Adult female mosquitoes were maintained in one-
pint cartons with organdy covering, and given water and sugar until
infection. To obtain DENV2 for infectious blood-meals, C6/36 cells
were infected at a MOI of 0.001 and maintained for 12–14 days with a
medium change at 7 days. Infected cells were scraped into the
medium, mixed with an equal volume of deﬁbrinated sheep blood,
and supplemented with ATP to a ﬁnal concentration of 1 mM. Adult
female mosquitoes 4–6 days post-emergence were starved of sugar
for 24 h, deprived of water for 4 h, and then exposed to the infectious
blood-meal for 45 min using a 37 °C water-jacketed glass feeding
device with a hog gut membrane. Virus titers in the blood-meals
ranged from 7.2 to 9.45 log10 TCID50/ml. In our experience with 30P-
NBX and E protein mutant viruses, there was no correlation between
virus titer in this range and midgut infectivity (data not shown). Fully
engorged mosquitoes were selected and maintained for 7 days, when
midguts were dissected in PBS, ﬁxed in 4% paraformaldehyde in PBS
overnight, and analyzed for virus antigen via IFA to determine midgut
infection rates. Each blood-feed experiment was repeated three times
with at least 23 mosquito midguts analyzed per experiment.
IT inoculations were performed as described previously (Huang
et al., 2010). C-1 virus seeds were diluted to 1×105 TCID50/ml and
adult female mosquitoes were IT inoculated with 0.3–0.5 μl of diluted
virus. Injected mosquitoes were maintained for 7 days until head
squashes were performed. Virus antigen was detected in head tissues
by IFA to determine infection rates. Each IT injection experiment was
repeated three times for a total of 76–100 mosquitoes for each virus.
Indirect immunoﬂuorescence assay (IFA) for mosquito tissues
Midgut and head squash IFAswere performed as described previously
(Brackney et al., 2008). Virus antigen in midguts and head squashes was
detected using ﬂavivirus E protein DII group-reactive mouse MAb 4G2
(ATCC, HB-112) in wash buffer (PBS, 0.05% TritonX-100) or PBS,
respectively. Secondary antibody was ImmunoPure biotin-labeled goat
anti-mouse IgG (Thermo Scientiﬁc) with 0.005% Evan's Blue counter-
stain, followed by streptavidin-ﬂuorescein (GE Healthcare). MIRs and
head infectivity rates were determined by dividing the number of virus
antigen-positivemidguts or head squashes by the total number analyzed.
Student's t tests (p-value 0.05)were performed using Excel 2002 and chi-
square analysis (p-value 0.05) was done using SAS 9.1.
Epitope mapping of the E protein
The antigenic structure of mutant DENV E proteins was analyzed
using a well deﬁned panel of DENVMabs (Roehrig et al., 1998), which
included MAbs reactive with E protein DI (1B4C-2), DII (6B6C-1 and
2H3), DIII (3H5, 9A3D-8, and 1A1D-2), and prM (2H2). Antibody
reactivity was assessed by IFA with MAb dilutions on acetone-ﬁxed
C6/36 cells infected with each mutant virus. Antibody endpoint
concentrations with a greater than 4-fold difference from that of
parent virus 30P-NBX were considered signiﬁcant.
334 S.M. Erb et al. / Virology 406 (2010) 328–335Fusion from within assay
The capacity of themutant viruses to fuse with host cell membranes
was assessed using infected C6/36 cells exposed to pH 5.5 medium in
the FFWI assay (Guirakhoo et al., 1993). Brieﬂy, C6/36 cells in 24-well
plateswere infectedwith virus at aMOI of 0.1 andmaintained for 7 days
in culture medium buffered to pH 7.7. The medium was removed and
the infected cells were exposed to fusionmedium buffered withMES to
pH 5.5 for 2 h. After the incubation period, the cells were re-exposed to
the pH 7.7 culture medium for an additional 24 h. Cells were stained
withHema-3quick stain (Fisher) and thenumber of cells andnucleiwas
counted for calculation of the fusion index and percent fusion (Huang
et al., 2010).
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